The company announced Q4 results during trading hours today, 30 May 2013.
Meanwhile, the S&P BSE Sensex was down 21.74 points or 0.11% at 20,125.90.
On BSE, 1.28 lakh shares were traded in the counter as against average daily volume of 5,472 shares in the past two weeks.
The stock witnessed high volatility after the result announcement. The stock surged as much as 5.1% to the days' high of Rs 827.40 so far during the day. The stock lost 1.17% to the day's low of Rs 778 so far during the day.
Cadila Healthcare said that the group filed 33 abbreviated new drug applications (ANDA) in FY 2013, taking the cumulative filings to 173. The group received 15 ANDA approvals in FY 2013 taking the total to 76 product approvals. The company filed 25 additional dossiers for new products in the European markets, taking the cumulative number of new product dossier filings to 161. The group filed 18 dossiers in Brazil taking the cumulative filings to 100. In Mexico, the group filed 6 new product dossiers, taking the cumulative filings to 20, Cadila Healthcare said in a statement.
Cadila Healthcare is a global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare products.
Powered by Capital Market - Live News